Conidial viability assay for rapid susceptibility testing of Aspergillus species

被引:34
作者
Balajee, SA
Marr, KA
机构
[1] Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA
[2] Univ Washington, Seattle, WA 98109 USA
关键词
D O I
10.1128/JCM.40.8.2741-2745.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Antifungal susceptibility testing of filamentous fungi has become more important given the recognition of drug-resistant organisms and the availability of therapies other than amphotericin B (AMB). As current microdilution and E-test methods are limited by a 2 to 3 day incubation time required to obtain results, a more rapid method for susceptibility testing of fungi is needed. We report here a flow cytometric assay that relies on conidial metabolism of the viability dye FUN-1. Conidia are incubated in media containing increasing concentrations of AMB for 3 h, exposed to FUN-1, and then analyzed by flow cytometry. Relative susceptibility to AMB can be measured both by forward and side scatter characteristics of the conidial population and by mean fluorescence intensity (MFI) of the dye. MIC, calculated as the concentration of AMB to yield 90% reduction in MFI relative to growth controls, was determined for 27 clinical isolates Aspergillus species and correlated well with the standard (i.e., NCCLS) method. The results of these studies illustrate a method by which AMB susceptibility can be rapidly and reproducibly determined by measuring conidial viability.
引用
收藏
页码:2741 / 2745
页数:5
相关论文
共 25 条
  • [1] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
    Bartizal, K
    Gill, CJ
    Abruzzo, GK
    Flattery, AM
    Kong, L
    Scott, PM
    Smith, JG
    Leighton, CE
    Bouffard, A
    Dropinski, JF
    Balkovec, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2326 - 2332
  • [2] Deere D, 1998, YEAST, V14, P147, DOI 10.1002/(SICI)1097-0061(19980130)14:2<147::AID-YEA207>3.3.CO
  • [3] 2-C
  • [4] In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (03) : 954 - 958
  • [5] NEW IN-VITRO ASSAY BASED ON GLUCOSE CONSUMPTION FOR DETERMINING ITRACONAZOLE AND AMPHOTERICIN-B ACTIVITIES AGAINST ASPERGILLUS-FUMIGATUS
    GARRIGUES, JC
    DEFONTENAY, GC
    LINAS, MD
    LAGENTE, M
    SEGUELA, JP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) : 2857 - 2862
  • [6] RAPID-DETERMINATION OF ANTIFUNGAL ACTIVITY BY FLOW-CYTOMETRY
    GREEN, L
    PETERSEN, B
    STEIMEL, L
    HAEBER, P
    CURRENT, W
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (04) : 1088 - 1091
  • [7] Rapid susceptibility testing of Candida albicans by flow cytometry
    Kirk, SM
    Callister, SM
    Lim, LCL
    Schell, RF
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (02) : 358 - 363
  • [8] MORPHOLOGICAL EFFECTS OF LIPOPEPTIDES AGAINST ASPERGILLUS-FUMIGATUS CORRELATE WITH ACTIVITIES AGAINST (1,3)-BETA-D-GLUCAN SYNTHASE
    KURTZ, MB
    HEATH, IB
    MARRINAN, J
    DREIKORN, S
    ONISHI, J
    DOUGLAS, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) : 1480 - 1489
  • [9] In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
    Lass-Flörl, C
    Kofler, G
    Kropshofer, G
    Hermans, J
    Kreczy, A
    Dierich, MP
    Niederwieser, D
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) : 497 - 502
  • [10] Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining
    Lass-Flörl, C
    Nagl, M
    Speth, C
    Ulmer, H
    Dierich, MP
    Würzner, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) : 124 - 128